vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and commercialize novel PDE4 inhibitor
vTv to receive
“We are pleased to expand our license with Newsoara to allow the further development and commercialization of HPP737 globally. The amendment strengthens our balance sheet with the upfront payment of
In addition to the upfront payment of
“Over the last several years, vTv and Newsoara have enjoyed a productive and collaborative relationship, and this exciting expansion of the relationship will help accelerate the clinical development of our highly differentiated and potential best-in-class PDE4 inhibitor, HPP737,” said
“We are pleased to expand our collaboration with vTv and secure global rights to HPP737, a highly differentiated oral PDE4 inhibitor with the potential to address unmet needs in inflammation-mediated disease,” said Dr.
HPP737, a selective phosphodiesterase type 4 (PDE4) inhibitor, has shown therapeutic activity in several animal models of inflammation. In phase 1 studies, HPP737 was well tolerated with little or no gastrointestinal distress. Preclinical and clinical data suggest that HPP737 may be able to expand the therapeutic use for this target, which has been limited by the side-effects of currently available PDE4 inhibitors.
About HPP737
HPP737 is a novel, potent, and selective phosphodiesterase type 4 (PDE4) inhibitor in development for the treatment of psoriasis. HPP737 has shown potent inhibition of interleukin-23 (IL-23) and tumor necrosis factor alpha (TNF-α) production in vitro and in vivo, as well as therapeutic activity in several animal models of inflammation. In addition, HPP737 showed target engagement ex vivo. PDE4 inhibitors increase intracellular cyclic adenosine monophosphate (AMP) levels, resulting in broad anti-inflammatory effects. However, the therapeutic potential of PDE4 inhibitors has historically been limited by dose-limiting adverse events, including nausea and emesis. Preclinical and clinical data to date suggest HPP737 may avoid some of the gastrointestinal side effects (e.g., nausea, vomiting, diarrhea) commonly associated with other PDE4 inhibitors.
About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).
Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
About Newsoara
Newsoara is a biopharmaceutical company established in 2018 dedicated to the discovery and development of innovative therapies that deliver differentiated and clinically valuable benefits to patients in three strategically focused therapeutic areas, namely, (i) autoimmune diseases, (ii) oncology and (iii) metabolic diseases. Each of these therapeutic areas is characterized by substantial unmet medical needs and high growth potential, positioning Newsoara to capture significant market opportunities in these therapeutic areas.
Newsoara adopts a global development strategy with a number of product candidates advancing clinical trials in
Forward-Looking Statement
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the satisfaction of the closing conditions set forth in the securities purchase agreement, the expected use of proceeds from the offering, the timing of our clinical trials, the anticipated effect of Phase 3 topline data on the Company, the benefits of cadisegliatin to people living with T1D, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and our other filings with the
Investor Contact
917-355-2395
jfraunces@lifesciadvisors.com
Media Contact
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com
Source: vTv Therapeutics Inc.